JP2017501972A - トリグリセリドの固体組成物及びその使用 - Google Patents

トリグリセリドの固体組成物及びその使用 Download PDF

Info

Publication number
JP2017501972A
JP2017501972A JP2016529444A JP2016529444A JP2017501972A JP 2017501972 A JP2017501972 A JP 2017501972A JP 2016529444 A JP2016529444 A JP 2016529444A JP 2016529444 A JP2016529444 A JP 2016529444A JP 2017501972 A JP2017501972 A JP 2017501972A
Authority
JP
Japan
Prior art keywords
less
solid composition
poly
solid
microns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016529444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501972A5 (https=
Inventor
ジョン クロップ
ジョン クロップ
ガブリエル モリス
ガブリエル モリス
エミル カッキス
エミル カッキス
スティーブン ジャングルス
スティーブン ジャングルス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ultragenyx Pharmaceutical Inc
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53058066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2017501972(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of JP2017501972A publication Critical patent/JP2017501972A/ja
Publication of JP2017501972A5 publication Critical patent/JP2017501972A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
JP2016529444A 2013-11-14 2014-11-14 トリグリセリドの固体組成物及びその使用 Pending JP2017501972A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904369P 2013-11-14 2013-11-14
US61/904,369 2013-11-14
PCT/US2014/065693 WO2015073816A1 (en) 2013-11-14 2014-11-14 Solid compositions of triglycerides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020041943A Division JP2020111585A (ja) 2013-11-14 2020-03-11 トリグリセリドの固体組成物及びその使用

Publications (2)

Publication Number Publication Date
JP2017501972A true JP2017501972A (ja) 2017-01-19
JP2017501972A5 JP2017501972A5 (https=) 2017-10-19

Family

ID=53058066

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016529444A Pending JP2017501972A (ja) 2013-11-14 2014-11-14 トリグリセリドの固体組成物及びその使用
JP2020041943A Pending JP2020111585A (ja) 2013-11-14 2020-03-11 トリグリセリドの固体組成物及びその使用
JP2022080251A Pending JP2022107017A (ja) 2013-11-14 2022-05-16 トリグリセリドの固体組成物及びその使用
JP2024106876A Pending JP2024129109A (ja) 2013-11-14 2024-07-02 トリグリセリドの固体組成物及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020041943A Pending JP2020111585A (ja) 2013-11-14 2020-03-11 トリグリセリドの固体組成物及びその使用
JP2022080251A Pending JP2022107017A (ja) 2013-11-14 2022-05-16 トリグリセリドの固体組成物及びその使用
JP2024106876A Pending JP2024129109A (ja) 2013-11-14 2024-07-02 トリグリセリドの固体組成物及びその使用

Country Status (18)

Country Link
US (6) US20160243071A1 (https=)
EP (2) EP3782610A1 (https=)
JP (4) JP2017501972A (https=)
KR (1) KR102291310B1 (https=)
CN (2) CN113181158A (https=)
AR (2) AR099353A1 (https=)
AU (1) AU2014348470B2 (https=)
CA (2) CA2929688C (https=)
CL (1) CL2016001130A1 (https=)
ES (1) ES2833294T3 (https=)
IL (1) IL245588B (https=)
MX (2) MX383005B (https=)
MY (1) MY177028A (https=)
PE (1) PE20161024A1 (https=)
PH (1) PH12016500821A1 (https=)
RU (1) RU2016123169A (https=)
TW (1) TWI640327B (https=)
WO (1) WO2015073816A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022107017A (ja) * 2013-11-14 2022-07-20 ウルトラジェニクス ファーマシューティカル インク． トリグリセリドの固体組成物及びその使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US12419852B2 (en) 2018-08-27 2025-09-23 Exerkine Corporation Method for treating lysosomal storage disease
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
CN113476408A (zh) * 2021-07-23 2021-10-08 兆科药业（广州）有限公司 一种苯丁酸甘油酯颗粒剂及其制备方法与应用

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06178664A (ja) * 1992-12-15 1994-06-28 Fuji Oil Co Ltd 水中油型乳化物の製造法
JPH0840891A (ja) * 1994-07-29 1996-02-13 Showa Sangyo Co Ltd リポ製剤
JPH08311480A (ja) * 1995-05-18 1996-11-26 D H Ee Kodo Seisei Chushutsu Gijutsu Kenkyu Kumiai 高純度トリアシルグリセロールからなる油脂の製造方法及び高度不飽和脂肪酸含有油脂組成物
JP2002536304A (ja) * 1999-02-05 2002-10-29 ベイラ、ユーニヴァーサティ、メディカル、センタ 炭素数が７である脂肪酸を含むトリグリセリドを含有する栄養補助剤または医薬調製物
US20060004099A1 (en) * 2004-07-02 2006-01-05 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
JP2007505124A (ja) * 2003-09-09 2007-03-08 スリーエム イノベイティブ プロパティズ カンパニー 抗菌組成物および方法
US20070123588A1 (en) * 2003-05-20 2007-05-31 Charles Roe R Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements
JP2008533048A (ja) * 2005-03-10 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー 耳の感染症の治療方法
JP2008537732A (ja) * 2005-03-10 2008-09-25 スリーエム イノベイティブ プロパティズ カンパニー ヒドロキシカルボン酸のエステルを含む抗菌組成物
JP2009107954A (ja) * 2007-10-29 2009-05-21 Nisshin Oillio Group Ltd 持久力向上剤、持久力向上用食品および持久力向上用医薬品
JP2009525992A (ja) * 2006-02-10 2009-07-16 スポーツコム デンマーク アプス コーティングを施した錠剤、その製造方法、及び関連する使用
JP2013528648A (ja) * 2010-06-14 2013-07-11 ベイラー リサーチ インスティテュート 成人ポリグルコサン小体病（ａｐｂｄ）を処置するためのトリヘプタノイン食
WO2013126990A1 (en) * 2012-03-01 2013-09-06 Prometic Bioscences Inc. Method for the preparation of triglycerides of medium-chain length fatty acids
WO2013158616A1 (en) * 2012-04-16 2013-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of medium-chain acyl-coa dehydrogenase deficiency

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337596A (en) 1965-02-18 1967-08-22 Procter & Gamble Synthesis of mixed glycerides
JPS5215834A (en) 1975-07-12 1977-02-05 Ajinomoto Kk Method of producing food composition
US4753963A (en) 1985-09-26 1988-06-28 The Procter & Gamble Company Nutritional fat suitable for enteral and parenteral products
JPH07102106B2 (ja) 1987-06-10 1995-11-08 日清製粉株式会社 経口，経管栄養食の製造法
KR100318295B1 (ko) 1989-07-05 2002-11-16 가부시키가이샤 저펜에너지 냉각윤활제
EP0421581A1 (en) 1989-10-03 1991-04-10 Warner-Lambert Company Chewable spray dried spheroidal microcapsules and wax coated microcapsules and methods for preparing same
JPH0692848A (ja) 1992-09-11 1994-04-05 Sagami Chem Res Center 糖尿病治療用乳剤
JPH06145688A (ja) 1992-11-10 1994-05-27 Nippon San Sekiyu Kk 冷凍機用潤滑油組成物
US5746933A (en) 1994-11-07 1998-05-05 Nippon Oil Co., Ltd. Lubricating oil and composition for refrigerating machine, and refrigerating machine
ES2157422T3 (es) 1995-02-07 2001-08-16 Brusilow Entpr Llc Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos.
US5698210A (en) 1995-03-17 1997-12-16 Lee County Mosquito Control District Controlled delivery compositions and processes for treating organisms in a column of water or on land
EP0903335B1 (en) 1995-09-25 2002-11-27 Kao Corporation Use of ester compounds in lubricating oil compositions
US5908631A (en) * 1997-02-27 1999-06-01 L'oreal S.A. Monohydric alcohol-free composition for topical use comprising solubilized ethylcellulose
US5885616A (en) 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6278006B1 (en) 1999-01-19 2001-08-21 Cargill, Incorporated Transesterified oils
US20030162833A1 (en) 2001-08-01 2003-08-28 Roe Charles R. Fatty acid treatment for cardiac patients
DE60130083T2 (de) 2000-10-16 2008-05-15 Nof Corp. Herstellung von Estern für die Verwendung als Basisschmieröl
JP4282289B2 (ja) 2002-08-29 2009-06-17 株式会社ジャパンエナジー 流体軸受用潤滑油及びそれを用いた流体軸受
JPWO2004022050A1 (ja) 2002-09-05 2005-12-22 日清オイリオグループ株式会社 脂質代謝調整剤および飲食物
WO2005120484A1 (ja) 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター
US7141114B2 (en) * 2004-06-30 2006-11-28 Rec Silicon Inc Process for producing a crystalline silicon ingot
FR2894822B1 (fr) 2005-12-20 2011-11-18 Pf Medicament Composition pharmaceutique contenant des acides gras omega-3
JP5099808B2 (ja) 2006-05-29 2012-12-19 独立行政法人農業・食品産業技術総合研究機構 脂質代謝改善用組成物
JP2010526123A (ja) 2007-05-08 2010-07-29 ディーエスエム アイピー アセッツ ビー．ブイ． 体重維持および体組成
CN102046202A (zh) 2008-03-26 2011-05-04 塔罗制药北美有限公司 用于口服药剂的稳定脂质组合物
PL3133396T3 (pl) 2008-04-29 2019-03-29 Horizon Therapeutics, Llc Sposób leczenia z zastosowaniem leków wychwytujących amoniak
PT3133396T (pt) 2008-08-29 2018-12-07 Immedica Pharma Ab Métodos de tratamento utilizando fármacos eliminadores de amoníaco
CA2785714C (en) 2009-12-30 2016-01-26 Baylor Research Institute Anaplerotic therapy for alzheimer's disease and the aging brain
US8932646B2 (en) 2010-06-18 2015-01-13 Bausch & Lomb Incorporated Peroxide contact lens care solution
CN101919453B (zh) * 2010-08-16 2013-04-10 苏州市佳禾食品工业有限公司 中碳链脂肪酸粉末油脂及其制备方法
JP5820256B2 (ja) 2011-02-10 2015-11-24 株式会社ファンケル 自己乳化製剤
WO2013012699A2 (en) 2011-07-15 2013-01-24 3M Innovative Properties Company Polyurethane based coating compositions
DK2760479T3 (en) 2011-09-30 2017-07-17 Horizon Therapeutics Llc Nitrogen-removing drug for use in a method of treating a nitrogen retention disorder
WO2013121906A1 (ja) 2012-02-15 2013-08-22 日清オイリオグループ株式会社 飼料用組成物、飼料、及び飼料の製造方法
ES2728727T3 (es) 2012-12-13 2019-10-28 Baylor Res Institute At Dallas Triheptanoína para el tratamiento de la deficiencia del transportador de glucosa 1
EP3027180B1 (en) 2013-07-31 2021-07-07 The Children's Hospital of Philadelphia Compositions and methods of the treatment of fatty acid metabolism disorders
TWI640327B (zh) 2013-11-14 2018-11-11 美商奧崔基尼克斯製藥公司 三酸甘油酯之固體組合物及其用途
US11844775B2 (en) 2018-07-11 2023-12-19 University of Pittsburgh—of the Commonwealth System of Higher Education Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06178664A (ja) * 1992-12-15 1994-06-28 Fuji Oil Co Ltd 水中油型乳化物の製造法
JPH0840891A (ja) * 1994-07-29 1996-02-13 Showa Sangyo Co Ltd リポ製剤
JPH08311480A (ja) * 1995-05-18 1996-11-26 D H Ee Kodo Seisei Chushutsu Gijutsu Kenkyu Kumiai 高純度トリアシルグリセロールからなる油脂の製造方法及び高度不飽和脂肪酸含有油脂組成物
JP2002536304A (ja) * 1999-02-05 2002-10-29 ベイラ、ユーニヴァーサティ、メディカル、センタ 炭素数が７である脂肪酸を含むトリグリセリドを含有する栄養補助剤または医薬調製物
US20070123588A1 (en) * 2003-05-20 2007-05-31 Charles Roe R Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements
JP2007505124A (ja) * 2003-09-09 2007-03-08 スリーエム イノベイティブ プロパティズ カンパニー 抗菌組成物および方法
US20060004099A1 (en) * 2004-07-02 2006-01-05 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
JP2008533048A (ja) * 2005-03-10 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー 耳の感染症の治療方法
JP2008537732A (ja) * 2005-03-10 2008-09-25 スリーエム イノベイティブ プロパティズ カンパニー ヒドロキシカルボン酸のエステルを含む抗菌組成物
JP2009525992A (ja) * 2006-02-10 2009-07-16 スポーツコム デンマーク アプス コーティングを施した錠剤、その製造方法、及び関連する使用
JP2009107954A (ja) * 2007-10-29 2009-05-21 Nisshin Oillio Group Ltd 持久力向上剤、持久力向上用食品および持久力向上用医薬品
JP2013528648A (ja) * 2010-06-14 2013-07-11 ベイラー リサーチ インスティテュート 成人ポリグルコサン小体病（ａｐｂｄ）を処置するためのトリヘプタノイン食
WO2013126990A1 (en) * 2012-03-01 2013-09-06 Prometic Bioscences Inc. Method for the preparation of triglycerides of medium-chain length fatty acids
WO2013158616A1 (en) * 2012-04-16 2013-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of medium-chain acyl-coa dehydrogenase deficiency

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, vol. 114(8), JPN6020013784, 2012, pages 889 - 895, ISSN: 0004251136 *
JOURNAL OF OLEO SCIENCE, vol. 62, no. 11, JPN6019012274, 6 November 2013 (2013-11-06), pages 893 - 900, ISSN: 0004011722 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022107017A (ja) * 2013-11-14 2022-07-20 ウルトラジェニクス ファーマシューティカル インク． トリグリセリドの固体組成物及びその使用
US12551461B2 (en) 2013-11-14 2026-02-17 Ultragenyx Pharmaceutical Inc. Compositions of triglycerides and uses thereof

Also Published As

Publication number Publication date
JP2020111585A (ja) 2020-07-27
AR099353A1 (es) 2016-07-20
US20200069631A1 (en) 2020-03-05
JP2022107017A (ja) 2022-07-20
MX2016006329A (es) 2016-09-06
JP2024129109A (ja) 2024-09-26
CN105764497A (zh) 2016-07-13
PH12016500821A1 (en) 2016-06-13
IL245588B (en) 2021-08-31
KR102291310B1 (ko) 2021-08-23
US20230181513A1 (en) 2023-06-15
EP3068383A1 (en) 2016-09-21
CL2016001130A1 (es) 2017-01-20
PE20161024A1 (es) 2016-11-10
AR130666A2 (es) 2025-01-08
ES2833294T3 (es) 2021-06-14
EP3068383A4 (en) 2017-11-08
EP3068383B1 (en) 2020-09-16
US20160243071A1 (en) 2016-08-25
WO2015073816A1 (en) 2015-05-21
AU2014348470A1 (en) 2016-05-26
US20250120936A1 (en) 2025-04-17
TW201609189A (zh) 2016-03-16
CN113181158A (zh) 2021-07-30
TWI640327B (zh) 2018-11-11
CA2929688A1 (en) 2015-05-21
MX2021001790A (es) 2021-04-19
RU2016123169A (ru) 2017-12-19
CA3197154A1 (en) 2015-05-21
US20250120934A1 (en) 2025-04-17
CA2929688C (en) 2023-06-13
US20250120935A1 (en) 2025-04-17
AU2014348470B2 (en) 2020-01-30
MY177028A (en) 2020-09-02
IL245588A0 (en) 2016-06-30
US12551461B2 (en) 2026-02-17
MX383005B (es) 2025-03-13
KR20160084407A (ko) 2016-07-13
EP3782610A1 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
US12551461B2 (en) Compositions of triglycerides and uses thereof
CA2231342C (fr) Composition pharmaceutique pour administration par voie orale
JPH0122245B2 (https=)
BE1015217A5 (https=)
MD4180C1 (ro) Procedeu de fabricare a compoziţiilor farmaceutice cu conţinut de rifaximină sub formă de microgranule gastrorezistente, compoziţii şi utilizarea lor în tratamentul afecţiunilor inflamatoare ale intestinelor
CN103889455B (zh) 稳定化乙哌立松医药组成物及含有上述组成物的缓释制剂
CN101010067B (zh) 莫达非尼口腔冻干剂
US20110135723A1 (en) Pharmaceutical compositions containing pregabalin
WO2009084041A2 (en) Pharmaceutical compositions of dexibuprofen
ES2836289T3 (es) Poliaminas biodisponibles
JP2008534584A (ja) フェノフィブラート含有メントール又はｐｅｇ／ポロキサマー混合物の改良製剤
EP1621186A1 (en) Modafinil oral lyophilizate
US11318090B1 (en) In situ gelling composition as a pH-selective and mucoadhesive sustained release drug delivery system
ES2733113T3 (es) Composición farmacéutica estable de una sal de vinorelbina soluble en agua
BR112016010583B1 (pt) Composição, composição farmacêutica e uso das mesmas
WO1992022305A1 (fr) Composition therapeutique pour liberation prolongee de magnesium
TW202541789A (zh) （ｚ）－因多昔芬（ｅｎｄｏｘｉｆｅｎ）之口服調配物及其使用方法
WO2016166767A1 (en) Pharmaceutical formulation comprising low melting, highly lipophilic drugs

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20160706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170908

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200311

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200311

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200319

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200323

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200410

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200420

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201102

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201214

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20201223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210518

C302 Record of communication

Free format text: JAPANESE INTERMEDIATE CODE: C302

Effective date: 20210608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210623

C141 Inquiry by the administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C141

Effective date: 20211004

C54 Written response to inquiry

Free format text: JAPANESE INTERMEDIATE CODE: C54

Effective date: 20220104

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220418

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220523

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220627

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220627